One Technology. Multiple Focused Companies.

Each validated Bionanomatrix™ application is treated as a standalone business opportunity from inception.

Once an application reaches sufficient scientific and clinical maturity, it is spun out into a dedicated operating company (NewCo) with:

• An exclusive, field-specific license
• Independent leadership and governance
• A focused clinical, regulatory, and commercial mandate

In return, Endomimetics receives a structured combination of:

• Upfront licensing fees
• Development and commercial milestones
• Ongoing royalties
• Equity participation in the NewCo

This approach aligns incentives while allowing each company to remain highly focused and acquisition-ready.

Targeting High-Impact, Capital-Efficient Indications

Our internal R&D efforts are selectively concentrated on clinical areas where Bionanomatrix™ provides a clear and defensible advantage.

Programs are prioritized based on:

• Unmet clinical need
• Probability of technical and regulatory success
• Partner and market demand
• Capital efficiency and scalability

Our lead application—Bionanomatrix™ gel for AVF maturation failure mitigation—serves as the first planned spinout, with an FDA IND submission targeted within the next 24 months.

Clear Entry Points. Defined Risk Profiles.

Our model is intentionally designed to separate platform risk from asset-specific risk, offering flexibility to different investor profiles

Platform Level (Endomimetics)

• Capital supports core IP, discovery, and early validation
• Provides diversified exposure across multiple future applications

Asset Level (Spinout Companies)

• Capital advances a single, focused indication
• Attracts investors seeking concentrated execution and defined exit paths

This structure creates transparency, optionality, and capital efficiency across the lifecycle of innovation.

Lean Operations. Focused Execution

Endomimetics maintains a lean central organization, dedicated to science, IP stewardship, and company creation.

Each spinout operates independently with:

• Its own executive team
• Responsibility for clinical trials, regulatory strategy, and commercialization
• Formalized license and technical support agreements with Endomimetics

This minimizes operational overlap while preserving scientific continuity.

Exit & Long-Term Value Creation

Built for Strategic Outcomes

Our business model functions as an innovation factory, producing both:

• Acquirable operating companies, structured for clean M&A or strategic licensing once key value inflection points are achieved
• A growing platform entity, whose aggregate equity stakes, royalties, and licenses compound in value over time

As multiple spinouts mature, Endomimetics itself becomes a compelling acquisition candidate for strategic buyers or financial sponsors seeking a permanent, scalable innovation engine.